Utility of 18F-FDG PET/CT uptake values in predicting response to neoadjuvant chemoimmunotherapy in resectable non-small cell lung cancer

被引：15

作者：

Zhuang, Fenghui ^{[1
]}

Huang, Jia ^{[2
]}

Wu, Junqi ^{[1
]}

Xu, Long ^{[1
]}

Zhang, Lei ^{[1
]}

Li, Qiang ^{[3
]}

Li, Chongwu ^{[1
]}

Zhao, Yue ^{[1
]}

Yang, Minglei ^{[4
]}

Ma, Minjie ^{[5
]}

She, Yunlang ^{[1
]}

Chen, Hezhong ^{[6
]}

Luo, Qingquan ^{[2
]}

Zhao, Deping ^{[1
,8
]}

Chen, Chang ^{[1
,5
,7
,8
]}

机构：

[1] Tongji Univ, Shanghai Pulm Hosp, Sch Med, Dept Thorac Surg, Shanghai, Peoples R China

[2] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Shanghai Lung Canc Ctr, Shanghai, Peoples R China

[3] Tongji Univ, Shanghai Pulm Hosp, Sch Med, Dept Nucl Med, Shanghai, Peoples R China

[4] Chinese Acad Sci, Ningbo 2 Hosp, Dept Thorac Surg, Zhejiang, Peoples R China

[5] Lanzhou Univ, Dept Thorac Surg, Hosp 1, Lanzhou, Gansu, Peoples R China

[6] Second Mil Med Univ, Changhai Hosp, Dept Thorac Surg, Shanghai, Peoples R China

[7] Linhai First Peoples Hosp, Taizhou, Zhejiang, Peoples R China

[8] Tongji Univ, Shanghai Pulm Hosp, Sch Med, Dept Thorac Surg, 507 Zhengmin Rd, Shanghai 200443, Peoples R China

来源：

LUNG CANCER | 2023年 / 178卷

基金：

中国国家自然科学基金; 国家重点研发计划;

关键词：

PET; CT; SUXmax; Major pathologic response; Neoadjuvant chemoimmunotherapy; Non-small cell lung cancer; POSITRON-EMISSION-TOMOGRAPHY; F-18-FDG PET/CT; EXPERT CONSENSUS; SINGLE-ARM; OPEN-LABEL; FDG-PET; CHEMOTHERAPY; THERAPY; RECOMMENDATIONS; IMMUNOTHERAPY;

D O I：

10.1016/j.lungcan.2023.02.001

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Introduction: Reliable predictive markers are lacking for resectable non-small cell lung cancer (NSCLC) patients treated with neoadjuvant chemoimmunotherapy. The present study investigated the utility of SUVmax values acquired from PET/CT to predict the response to neoadjuvant chemoimmunotherapy for resectable NSCLC.Materal and methods: SUVmax, clinical and pathological outcomes, were collected from patients in 5 hospitals. Patients who received dynamic PET/CT surveillance were divided into cohorts A (chemoimmunotherapy) and B (chemotherapy), respectively, while cohort C (chemoimmunotherapy) comprised patients undergoing post-therapy PET/CT. Associations between SUVmax and major pathologic response (MPR) were evaluated through receiver operating characteristic (ROC) curves.Results: A total of 129 cases with an MPR rate of 46.5 % was identified. In neoadjuvant chemoimmunotherapy, Delta SUVmax% (AUC: 0.890, 95 % CI: 0.761-0.949) and post-therapy SUVmax (AUC: 0.933, 95 % CI: 0.802-0.959) could accurately predict MPR. On the contrary, the baseline SUVmax was not associated with MPR (p = 0.184). Furthermore, an independent cohort C proved that post-therapy SUVmax could serve as an independent predictor (AUC: 0.928, 95 % CI: 0.823-0.958). In addition, robust predictive performance could be observed when we use the optimal cut-off point of both Delta SUVmax% (54.4 %, AUC: 0.912, 95 % CI: 0.824-0.994) and post-therapy SUVmax (3.565, AUC: 0.912, 95 % CI: 0.824-0.994) in neoadjuvant chemoimmunotherapy. The RNA data revealed that the expression of PFKFB4, a key enzyme in glycolysis, was positively correlated with SUVmax value and tumor cell proliferation after neoadjuvant chemoimmunotherapy.Conclusion: These findings highlighted that the Delta SUVmax% and remained SUVmax were accurate and non-invasive tests for the prediction of MPR after neoadjuvant chemoimmunotherapy.

引用

页码：20 / 27

页数：8

共 50 条

[1] Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium [J].

Amaria, Rodabe N. ;

Menzies, Alexander M. ;

Burton, Elizabeth M. ;

Scolyer, Richard A. ;

Tetzlaff, Michael T. ;

Antdbacka, Robert ;

Ariyan, Charlotte ;

Bassett, Roland ;

Carter, Brett ;

Daud, Adil ;

Faries, Mark ;

Fecher, Leslie A. ;

Flaherty, Keith T. ;

Gershenwald, Jeffrey E. ;

Hamid, Omid ;

Hong, Angela ;

Kirkwood, John M. ;

Lo, Serigne ;

Margolin, Kim ;

Messina, Jane ;

Postow, Michael A. ;

Rizos, Helen ;

Ross, Merrick I. ;

Rozeman, Elisa A. ;

Saw, Robyn P. M. ;

Sondak, Vernon ;

Sullivan, Ryan J. ;

Taube, Janis M. ;

Thompson, John F. ;

van de Wiel, Bart A. ;

Eggermont, Alexander M. ;

Davies, Michael A. ;

Ascierto, Paolo A. ;

Spillane, Andrew J. ;

van Akkooi, Alexander C. J. ;

Wargo, Jennifer A. ;

Blank, Christian U. ;

Tawbi, Hussein A. ;

Long, Georgina V. .

LANCET ONCOLOGY, 2019, 20 (07) :E378-E389

[2] Is 18F-FDG PET/CT Useful for the Early Prediction of Histopathologic Response to Neoadjuvant Erlotinib in Patients with Non-Small Cell Lung Cancer? [J].

Aukema, Tjeerd S. ;

Kappers, Ingrid ;

Olmos, Renato A. Valdes ;

Codrington, Henk E. ;

van Tinteren, Harm ;

van Pel, Renee ;

Klomp, Houke M. .

JOURNAL OF NUCLEAR MEDICINE, 2010, 51 (09) :1344-1348

[3] Nodal immune flare mimics nodal disease progression following neoadjuvant immune checkpoint inhibitors in non-small cell lung cancer [J].

Cascone, Tina ;

Weissferdt, Annikka ;

Godoy, Myrna C. B. ;

William, William N., Jr. ;

Leung, Cheuk H. ;

Lin, Heather Y. ;

Basu, Sreashi ;

Yadav, Shalini S. ;

Pataer, Apar ;

Mitchell, Kyle G. ;

Khan, Md Abdul Wadud ;

Shi, Yushu ;

Haymaker, Cara ;

Solis, Luisa M. ;

Parra, Edwin R. ;

Kadara, Huam ;

Wistuba, Ignacio I. ;

Sharma, Padmanee ;

Allison, James P. ;

Ajami, Nadim J. ;

Wargo, Jennifer A. ;

Jenq, Robert R. ;

Gibbons, Don L. ;

Lee, J. Jack ;

Swisher, Stephen G. ;

Vaporciyan, Araa ;

Heymach, John, V ;

Sepesi, Boris .

NATURE COMMUNICATIONS, 2021, 12 (01)

[4] Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial [J].

Cascone, Tina ;

William, William N., Jr. ;

Weissferdt, Annikka ;

Leung, Cheuk H. ;

Lin, Heather Y. ;

Pataer, Apar ;

Godoy, Myrna C. B. ;

Carter, Brett W. ;

Federico, Lorenzo ;

Reuben, Alexandre ;

Khan, Md Abdul Wadud ;

Dejima, Hitoshi ;

Francisco-Cruz, Alejandro ;

Parra, Edwin R. ;

Solis, Luisa M. ;

Fujimoto, Junya ;

Tran, Hai T. ;

Kalhor, Neda ;

Fossella, Frank V. ;

Mott, Frank E. ;

Tsao, Anne S. ;

Blumenschein, George, Jr. ;

Le, Xiuning ;

Zhang, Jianjun ;

Skoulidis, Ferdinandos ;

Kurie, Jonathan M. ;

Altan, Mehmet ;

Lu, Charles ;

Glisson, Bonnie S. ;

Byers, Lauren Averett ;

Elamin, Yasir Y. ;

Mehran, Reza J. ;

Rice, David C. ;

Walsh, Garrett L. ;

Hofstetter, Wayne L. ;

Roth, Jack A. ;

Antonoff, Mara B. ;

Kadara, Humam ;

Haymaker, Cara ;

Bernatchez, Chantale ;

Ajami, Nadim J. ;

Jenq, Robert R. ;

Sharma, Padmanee ;

Allison, James P. ;

Futreal, Andrew ;

Wargo, Jennifer A. ;

Wistuba, Ignacio I. ;

Swisher, Stephen G. ;

Lee, J. Jack ;

Gibbons, Don L. .

NATURE MEDICINE, 2021, 27 (03) :504-+

[5] 18F-FDG PET/CT to Predict Response to Neoadjuvant Chemotherapy and Prognosis in Inflammatory Breast Cancer [J].

Champion, Laurence ;

Lerebours, Florence ;

Alberini, Jean-Louis ;

Fourme, Emmanuelle ;

Gontier, Eric ;

Bertrand, Francoise ;

Wartski, Myriam .

JOURNAL OF NUCLEAR MEDICINE, 2015, 56 (09) :1315-1321

[6]

Chen T., 2021, ANN THORAC SURG

[7]

Chen Z.Y., THORAC CANCER, V13, P2022

[8] Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC) [J].

Cottrell, T. R. ;

Thompson, E. D. ;

Forde, P. M. ;

Stein, J. E. ;

Duffield, A. S. ;

Anagnostou, V. ;

Rekhtman, N. ;

Anders, R. A. ;

Cuda, J. D. ;

Illei, P. B. ;

Gabrielson, E. ;

Askin, F. B. ;

Niknafs, N. ;

Smith, K. N. ;

Velez, M. J. ;

Sauters, J. L. ;

Isbell, J. M. ;

Jones, D. R. ;

Battafarano, R. J. ;

Yang, S. C. ;

Danilova, L. ;

Wolchok, J. D. ;

Topalian, S. L. ;

Velculescu, V. E. ;

Pardoll, D. M. ;

Brahmer, J. R. ;

Hellmann, M. D. ;

Chaft, J. E. ;

Cimino-Mathews, A. ;

Taube, J. M. .

ANNALS OF ONCOLOGY, 2018, 29 (08) :1853-1860

[9] Role of interim 18F-FDG-PET/CT for the early prediction of clinical outcomes of Non-Small Cell Lung Cancer (NSCLC) during radiotherapy or chemo-radiotherapy. A systematic review [J].

Cremonesi, Marta ;

Gilardi, Laura ;

Ferrari, Mahila Esmeralda ;

Piperno, Gaia ;

Travaini, Laura Lavinia ;

Timmerman, Robert ;

Botta, Francesca ;

Baroni, Guido ;

Grana, Chiara Maria ;

Ronchi, Sara ;

Ciardo, Delia ;

Jereczek-Fossa, Barbara Alicja ;

Garibaldi, Cristina ;

Orecchia, Roberto .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 (11) :1915-1927

[10] De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017 [J].

Curigliano, G. ;

Burstein, H. J. ;

Winer, E. P. ;

Gnant, M. ;

Dubsky, P. ;

Loibl, S. ;

Colleoni, M. ;

Regan, M. M. ;

Piccart-Gebhart, M. ;

Senn, H. -J. ;

Thurlimann, B. ;

Andre, F. ;

Baselga, J. ;

Bergh, J. ;

Bonnefoi, H. ;

Brucker, S. Y. ;

Cardoso, F. ;

Carey, L. ;

Ciruelos, E. ;

Cuzick, J. ;

Denkert, C. ;

Di Leo, A. ;

Ejlertsen, B. ;

Francis, P. ;

Galimberti, V. ;

Garber, J. ;

Gulluoglu, B. ;

Goodwin, P. ;

Harbeck, N. ;

Hayes, D. F. ;

Huang, C. -S. ;

Huober, J. ;

Khaled, H. ;

Jassem, J. ;

Jiang, Z. ;

Karlsson, P. ;

Morrow, M. ;

Orecchia, R. ;

Osborne, K. C. ;

Pagani, O. ;

Partridge, A. H. ;

Pritchard, K. ;

Ro, J. ;

Rutgers, E. J. T. ;

Sedlmayer, F. ;

Semiglazov, V. ;

Shao, Z. ;

Smith, I. ;

Toi, M. ;

Tutt, A. .

ANNALS OF ONCOLOGY, 2017, 28 (08) :1700-1712

← 1 2 3 4 5 →